<DOC>
	<DOCNO>NCT01946815</DOCNO>
	<brief_summary>Natural course intermediate coronary artery disease ( CAD ) important predict prognosis patient disease . Several study well demonstrate beneficial effect lipid-lowering therapy progression CAD modification lipid profile . This effect also explain intravascular ultrasound ( IVUS ) optical coherence tomography . However , effect plaque modification coronary physiology rarely evaluate . This research evaluate change intermediate nonculprit coronary lesion lipid-lowering therapy via IVUS ( optional ) FFR .</brief_summary>
	<brief_title>Effect Atorvastatin Fractional Flow Reserve Coronary Artery Disease</brief_title>
	<detailed_description>The patient intermediate CAD ( 30-80 % diameter stenosis visual estimation ) FFR≥0.80 , nonculprit coronary artery disease FFR≥0.8 culprit coronary artery disease intervention enrol . FFR , IVUS ( optional ) index microcirculatory resistance ( IMR ) perform simultaneously . Atorvastatin 20mg start dose , up-titration do twice within 4~6weeks LDL target goal ( ① LDL &lt; 70mg/dl , ② statin naive : &gt; 50 % reduction baseline LDL , current statin user : &gt; 30 % reduction baseline LDL ) . First titration atorvastatin 40mg , second atorvastatin 80mg . If patient adverse effect atorvastatin , dose atorvastatin adjust investigator 's decision . Official clinical follow-up except visit statin dose titration occur 1 , 12 month index procedure . Follow-up coronary angiography , FFR , IMR , IVUS ( optional ) perform 12 month index procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>patient &gt; 18 year age willing participate patient stable intermediate CAD ( 3080 % diameter stenosis visual estimation ) angiography FFR≥0.8 , nonculprit CAD plan revascularization Signed write Informed Consent Patients cardiogenic shock Patients LVEF &lt; 35 % Patients leave main disease , restenotic , bypass graft lesion Patients platelet count &lt; 100,000 cell/mm3 Patients comorbidity reduce life expectancy one year Patients history stroke transient ischemic attack within 6 month Patients planned discontinuation medication due surgery Patients know adverse reaction HMG COA reductase therapy ( statin ) Patients liver disease ( elevation AST ALT 2 time ) Patient creatinine &gt; 2.0 mg/dL Pregnant woman woman childbearing potential intend child duration trial Patients consistently must take drug affect lipid level blood except investigational product</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>